Collegeville, PA, United States of America

Stuart Paul Romeril

USPTO Granted Patents = 14 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 9.4

ph-index = 5

Forward Citations = 79(Granted Patents)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

patents

2 out of 92

Glaxosmithkline Intellectual Property (no.2) Limited

patents

4. 1 out of 262

Cancer Research Technology Limited

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

14 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12285436 - Substituted pyridines as DNMT1 inhibitors (2025-04-29),

2. 11771711 - Substituted pyridines as DNMT1 inhibitors (2023-10-03),

3. 11377440 - Modulators of stimulator of interferon genes (STING) (2022-07-05),

4. 10975056 - Substituted pyridines as inhibitors of DNMT1 (2021-04-13),

5. 9790212 - Enhancer of zeste homolog 2 inhibitors (2017-10-17),

6. 9505745 - Enhancer of zeste homolog 2 inhibitors (2016-11-29),

7. 9402836 - Indoles (2016-08-02),

8. 9073924 - Azaindazoles (2015-07-07),

9. 9018382 - Indazoles (2015-04-28),

10. 8975291 - Indoles (2015-03-10),

11. 8846935 - Indazoles (2014-09-30),

12. 8697685 - Chemical compounds (2014-04-15),

13. 8637509 - Azaindazoles (2014-01-28),

14. 8598156 - Chemical compounds (2013-12-03),

Title: The Innovative Contributions of Stuart Paul Romeril

Introduction

Stuart Paul Romeril is a notable inventor based in Collegeville, PA (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 14 patents to his name, Romeril has made strides in developing innovative compounds that target critical health issues.

Latest Patents

Among his latest patents, Romeril has focused on substituted pyridines as DNA methyltransferase 1 (DNMT1) inhibitors. This invention relates to substituted pyridine derivatives that inhibit the activity of DNMT1. The invention also encompasses pharmaceutical compositions that include these compounds and methods for using them in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases linked to inappropriate DNMT1 activity.

Career Highlights

Throughout his career, Romeril has worked with prominent companies such as GlaxoSmithKline LLC and GlaxoSmithKline Intellectual Property Development Limited. His work in these organizations has allowed him to contribute to the advancement of medical science and therapeutic solutions.

Collaborations

Romeril has collaborated with esteemed colleagues, including William Henry Miller and Neil W Johnson. These partnerships have further enriched his research and development efforts.

Conclusion

Stuart Paul Romeril's innovative work in the pharmaceutical industry, particularly in developing DNMT1 inhibitors, showcases his commitment to addressing significant health challenges. His contributions continue to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.